ATE311191T1 - Apoptotische körper zur verwendung in der behandlung von t-zell-vermittelten- und entzündungserkrankungen - Google Patents
Apoptotische körper zur verwendung in der behandlung von t-zell-vermittelten- und entzündungserkrankungenInfo
- Publication number
- ATE311191T1 ATE311191T1 AT01935896T AT01935896T ATE311191T1 AT E311191 T1 ATE311191 T1 AT E311191T1 AT 01935896 T AT01935896 T AT 01935896T AT 01935896 T AT01935896 T AT 01935896T AT E311191 T1 ATE311191 T1 AT E311191T1
- Authority
- AT
- Austria
- Prior art keywords
- mediated
- cell
- treatment
- inflammatory diseases
- apoptotic body
- Prior art date
Links
- 230000001640 apoptogenic effect Effects 0.000 title abstract 4
- 208000027866 inflammatory disease Diseases 0.000 title abstract 2
- 238000011282 treatment Methods 0.000 title abstract 2
- 210000004027 cell Anatomy 0.000 abstract 2
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/22—Immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Reproductive Health (AREA)
- Transplantation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA 2309518 CA2309518A1 (en) | 2000-05-25 | 2000-05-25 | Apoptotic entities for use in treatment of t-cell-mediated and inflammatory disorders |
| PCT/CA2001/000758 WO2001089536A2 (en) | 2000-05-25 | 2001-05-25 | Apoptotic entities for use in treatment of t-cell-mediated and inflammatory disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE311191T1 true ATE311191T1 (de) | 2005-12-15 |
Family
ID=4166254
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01935896T ATE311191T1 (de) | 2000-05-25 | 2001-05-25 | Apoptotische körper zur verwendung in der behandlung von t-zell-vermittelten- und entzündungserkrankungen |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20020051771A1 (enExample) |
| EP (2) | EP1669081A1 (enExample) |
| JP (1) | JP2003534281A (enExample) |
| AT (1) | ATE311191T1 (enExample) |
| AU (1) | AU2001261986A1 (enExample) |
| CA (1) | CA2309518A1 (enExample) |
| DE (1) | DE60115432T2 (enExample) |
| DK (1) | DK1289534T3 (enExample) |
| ES (1) | ES2254424T3 (enExample) |
| TW (1) | TWI249404B (enExample) |
| WO (1) | WO2001089536A2 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2309424A1 (en) * | 2000-05-25 | 2001-11-25 | Vasogen Ireland Limited | Apoptotic entities for use in treatment of neurodegenerative and other neurological disorders |
| CA2327631A1 (en) * | 2000-12-05 | 2002-06-05 | Vasogen Ireland Limited | Inflammatory cytokine secretion inhibition |
| WO2003015850A1 (en) * | 2001-08-13 | 2003-02-27 | Edelson Richard Leslie | Method for inducing selectively suppressed immune response |
| US7727523B2 (en) * | 2001-08-13 | 2010-06-01 | Yale University | Method for suppressing immune system response to transplanted tissue or cells |
| CA2468197A1 (en) * | 2001-11-29 | 2003-06-05 | Therakos, Inc. | Methods for pretreating a subject with extracorporeal photopheresis and/or apoptotic cells |
| US8524495B2 (en) * | 2007-05-16 | 2013-09-03 | Yale University | Methods for inducing the differentiation of blood monocytes into functional dendritic cells |
| US10077426B2 (en) | 2012-12-06 | 2018-09-18 | Enlivex Therapeutics Ltd | Therapeutic apoptotic cell preparations, method for producing same and uses thereof |
| WO2016132366A1 (en) | 2015-02-18 | 2016-08-25 | Enlivex Therapeutics Ltd. | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11304976B2 (en) | 2015-02-18 | 2022-04-19 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11318163B2 (en) | 2015-02-18 | 2022-05-03 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11497767B2 (en) | 2015-02-18 | 2022-11-15 | Enlivex Therapeutics R&D Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11596652B2 (en) | 2015-02-18 | 2023-03-07 | Enlivex Therapeutics R&D Ltd | Early apoptotic cells for use in treating sepsis |
| US11000548B2 (en) | 2015-02-18 | 2021-05-11 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| AU2016250570B2 (en) | 2015-04-21 | 2021-07-01 | Enlivex Therapeutics Rdo Ltd | Therapeutic pooled blood apoptotic cell preparations and uses thereof |
| CN109069539A (zh) * | 2016-02-18 | 2018-12-21 | 恩立夫克治疗有限责任公司 | 用于癌症治疗的联合免疫疗法和细胞因子控制疗法 |
| WO2023209709A1 (en) * | 2022-04-27 | 2023-11-02 | Enlivex Therapeutics Rdo Ltd | Apoptotic cell - chemotherapy combination therapy |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5980954A (en) * | 1992-02-07 | 1999-11-09 | Vasogen Ireland Limited | Treatment of autoimmune diseases |
| CA2309424A1 (en) * | 2000-05-25 | 2001-11-25 | Vasogen Ireland Limited | Apoptotic entities for use in treatment of neurodegenerative and other neurological disorders |
| CA2309417A1 (en) * | 2000-05-25 | 2001-11-25 | Anthony E. Bolton | Apoptotic entities for use in treatment of endothelium dysfunction disorders |
| CA2468197A1 (en) * | 2001-11-29 | 2003-06-05 | Therakos, Inc. | Methods for pretreating a subject with extracorporeal photopheresis and/or apoptotic cells |
-
2000
- 2000-05-25 CA CA 2309518 patent/CA2309518A1/en not_active Abandoned
-
2001
- 2001-05-25 JP JP2001585780A patent/JP2003534281A/ja not_active Withdrawn
- 2001-05-25 DE DE2001615432 patent/DE60115432T2/de not_active Expired - Fee Related
- 2001-05-25 US US09/866,488 patent/US20020051771A1/en not_active Abandoned
- 2001-05-25 DK DK01935896T patent/DK1289534T3/da active
- 2001-05-25 AU AU2001261986A patent/AU2001261986A1/en not_active Abandoned
- 2001-05-25 EP EP20050025962 patent/EP1669081A1/en not_active Withdrawn
- 2001-05-25 AT AT01935896T patent/ATE311191T1/de not_active IP Right Cessation
- 2001-05-25 EP EP01935896A patent/EP1289534B1/en not_active Expired - Lifetime
- 2001-05-25 ES ES01935896T patent/ES2254424T3/es not_active Expired - Lifetime
- 2001-05-25 WO PCT/CA2001/000758 patent/WO2001089536A2/en not_active Ceased
- 2001-06-01 TW TW90113342A patent/TWI249404B/zh not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| HK1055079A1 (en) | 2003-12-24 |
| EP1669081A1 (en) | 2006-06-14 |
| WO2001089536A3 (en) | 2002-08-01 |
| EP1289534B1 (en) | 2005-11-30 |
| DE60115432T2 (de) | 2006-08-24 |
| JP2003534281A (ja) | 2003-11-18 |
| ES2254424T3 (es) | 2006-06-16 |
| WO2001089536A2 (en) | 2001-11-29 |
| DE60115432D1 (de) | 2006-01-05 |
| CA2309518A1 (en) | 2001-11-25 |
| US20020051771A1 (en) | 2002-05-02 |
| DK1289534T3 (da) | 2006-03-20 |
| AU2001261986A1 (en) | 2001-12-03 |
| EP1289534A2 (en) | 2003-03-12 |
| TWI249404B (en) | 2006-02-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE311191T1 (de) | Apoptotische körper zur verwendung in der behandlung von t-zell-vermittelten- und entzündungserkrankungen | |
| ATE102062T1 (de) | Niederfrequenz-elektrotherapiegeraet. | |
| ATE184792T1 (de) | 2-bromomelatonin zur behandlung von schlafstörungen | |
| ATE158182T1 (de) | Arzneimittel sowie deren herstellung und deren verwendung bei der bekämpfung von schmerzen und/oder entzündungen an tieren und menschen | |
| BR9811825A (pt) | Uso de lactobacillus para redução do nìvel de fibrinogênio no sangue | |
| ATE227587T1 (de) | Kombinierte verwendung von hyaluronsäure und therapeutischen wirkstoffen zur verbesserung des therapeutischen effekts | |
| DE69400799D1 (de) | Verwendung von riluzol zur behandlung von parkinson und den parkinson-syndromen | |
| ATE111735T1 (de) | Verwendung des wirkstoffs azelastin und glycerinethern zur bekämpfung von psoriasis- erkrankungen. | |
| DE4394931T1 (de) | Verwendung von Norastemizol zur Behandlung von allergischen Erkrankungen | |
| ATE81984T1 (de) | Verwendung von granulozyt-makrophagen-kolonie erregenden faktor zur herstellung eines medikaments zur behandlung von bakterieller krankheiten. | |
| BR0307041A (pt) | Corpos de fosfolipìdio e uso dos mesmos no tratamento de doenças inflamatórias e autoimunes | |
| ATE366581T1 (de) | Apoptotische körper zur verwendung in der behandlung von neurodegenerativen und sonstigen nervenerkrankungen | |
| ATE289805T1 (de) | Verwendung von antiseptika zur herstelllung von arzneimitteln zur prophylaxe und behandlung von infektionen und/ oder funktionellen gewebeumformungen im körperinneren | |
| DE3850154D1 (de) | Verwendung von Gepiron zur Herstellung eines pharmazeutischen Präparats zur Behandlung atypischer Depression. | |
| ATE126061T1 (de) | Verwendung von lithium zur behandlung oder prophylaxe von molluscum contagiusum. | |
| ATE316379T1 (de) | Oxyhuminsäure und ihre verwendung zur behandlung von verschiedenenen störungen | |
| RU93038888A (ru) | Салфетка из тканого углеродного материала | |
| WO2001089538A3 (en) | Apoptotic entities for use in treatment of endothelium dysfunction disorders | |
| ATE417620T1 (de) | Antipyretikum und herstellungsverfahren dafür | |
| DE59504374D1 (de) | Verwendung von Deoxyspergualin zur Herstellung eines Arzneimittels zur Behandlung von entzündlich-hyperreaktiven Erkrankungen | |
| GB0202410D0 (en) | Treatment of IL deficiencies | |
| ATE291919T1 (de) | Verwendung von adatanserin zur behandlung von akuten neurodegenerativen erkrankungen | |
| ATE136776T1 (de) | Verwendung von heptastigmin zur behandlung der zerebralen ictus | |
| BG107546U (en) | Balm for the restoration of skin impairments |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1289534 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |